When Should Radiation Be Avoided in the Treatment of Rectal Cancer?

Chapter

Abstract

The National Cancer Institute (NCI) Consensus Conference concluded in 1990 that chemotherapy plus concurrent radiation (chemoradiation) was the standard postoperative adjuvant treatment for all patients with pT3 and/or N1-2 rectal cancer [1]. This recommendation was based on phase III trials that compared postoperative chemoradiation arms with control arms of either surgery alone or surgery plus postoperative irradiation (Mayo/NCCTG 79-47-51) and demonstrated improvements in both disease-free and overall survival [2]. The standard design in US trials was to deliver six cycles of bolus 5-fluorouracil (5-FU)–based chemotherapy; concurrent irradiation was also given during cycles 3 and 4.

References

  1. 1.
    (1990) National Institutes of Health consensus conference: adjuvant therapy for patients with colon and rectal cancer. J Am Med Assoc 264:1444–1450Google Scholar
  2. 2.
    Krook JE, Moertel CG, Gunderson LL et al (1991) Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 324:709–715CrossRefPubMedGoogle Scholar
  3. 3.
    Sauer R, Becker H, Hohenberger P et al (2004) Preoperative chemoradiotherapy as compared with postoperative chemoradiotherapy for locally advanced rectal cancer. New Engl J Med 351:11–20CrossRefGoogle Scholar
  4. 4.
    Green FL, Stewart AK, Norton HJ (2004) New tumor-node-metastasis staging system for node-positive (stage III) rectal cancer: an analysis. J Clin Oncol 22:1778–1784CrossRefGoogle Scholar
  5. 5.
    Nissan A, Stojadinovic A, Shia J et al (2006) Predictors of recurrence in patients with T2 and early T3, N0 adenocarcinoma of the rectum treated with surgery alone. J Clin Oncol 24:4078–4084CrossRefPubMedGoogle Scholar
  6. 6.
    Kim JH, Beets GL, Kim MJ et al (2004) High-resolution MR imaging for nodal staging in rectal cancer: are there any criteria in addition to the size? Eur J Radiol 52:78–83CrossRefPubMedGoogle Scholar
  7. 7.
    Leibold T, Shia J, Ruo L et al (2008) Prognostic implications of the distribution of lymph node metastasis rectal cancer after neoadjuvant chemotherapy. J Clin Oncol 26:2106–2111CrossRefPubMedGoogle Scholar
  8. 8.
    Guillem JG, Diaz-Gonzalez J, Minsky BD et al (2008) cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. J Clin Oncol 26:368–373CrossRefPubMedGoogle Scholar
  9. 9.
    Mendenhall WM, Bland KI, Rout WR et al (1988) Clinically resectable adenocarcinoma of the rectum treated with preoperative irradiation and surgery. Dis Colon Rectum 31:287–290CrossRefPubMedGoogle Scholar
  10. 10.
    Schrag D, Weiser MR, Goodman KA et al (2014) Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol 32:513–518CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Patel UB, Brown G, Machado I et al (2017) MRI assessemnt and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long term results of the GEMCAD 0801 trial. Ann Oncol 28:344–353Google Scholar
  12. 12.
    Nagtegaal ID, Quirke P (2008) What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol 26:303–312CrossRefPubMedGoogle Scholar
  13. 13.
    Nagtegaal ID, van de Velde CJH, Marijnen CAM et al (2005) Low rectal cancer: a call for a change of approach in abdominoperineal resection. J Clin Oncol 23:9257–9264CrossRefPubMedGoogle Scholar
  14. 14.
    Bail SH, Kim NK, Lee YC et al (2007) Prognostic significance of circumferential resection margin following total mesorectal excision and adjuvant chemoradiotherapy in patients with rectal cancer. Ann Surg Oncol 14:462–469CrossRefGoogle Scholar
  15. 15.
    Al-Sukhni E, Milot L, Fruitman M et al (2012) Diagnostic accuracy of MRI for assessment of T category, lymph node metastasis, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis. Ann Surg Oncol 19:2212–2223CrossRefPubMedGoogle Scholar
  16. 16.
    Patel UB, Taylor F, Blomqvist L et al (2011) Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol 29:3753–3760CrossRefPubMedGoogle Scholar
  17. 17.
    Sebag-Montefiore D, Stephens RJ, Steele R et al (2009) Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicenter, randomised trial. Lancet 373:811–820CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Marijnen CAM, Nagtegaal ID, Kapiteijn E et al (2003) Radiotherapy does not compensate for positive resection margins in rectal cancer patients: report of a multicenter randomized trial. Int J Radiat Oncol Biol Phys 55:1311–1320CrossRefPubMedGoogle Scholar
  19. 19.
    Peeters KCMJ, Marijnen CAM, Nagtegaal ID et al (2007) The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 246:693–701CrossRefPubMedGoogle Scholar
  20. 20.
    Birgisson H, Pahlman L, Glimelius B (2005) Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish rectal cancer trial. J Clin Oncol 23:8697–8705CrossRefPubMedGoogle Scholar
  21. 21.
    Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al (2006) Long term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 93:1215–1223CrossRefPubMedGoogle Scholar
  22. 22.
    Sauer R, Roedel C (2005) The author’s reply. New Engl J Med 352:510–511Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2018

Authors and Affiliations

  1. 1.Department of Radiation OncologyUniversity of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations